Genetic diversity and medicinal drug response in eye care

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 248, Issue 8, 2010, Pages 1057-1061

  Shastry, Barkur S ^a  

^a OAKLAND UNIVERSITY   (United States)

Author keywords

Genetics; Medicine; Ophthalmology; Polymorphism

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; GLUCOCORTICOID; LATANOPROST; PREDNISOLONE ACETATE; RANIBIZUMAB; TIMOLOL; TRIAMCINOLONE ACETONIDE; VERTEPORFIN;

ADVERSE DRUG REACTION; BLOOD PRESSURE; BRADYCARDIA; DNA POLYMORPHISM; DRUG DEVELOPMENT; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; DYSPNEA; ENDOPHTHALMITIS; EYE CARE; EYE DISCHARGE; EYE SWELLING; FEVER; FOOT EDEMA; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; GLAUCOMA; HEART INFARCTION; HUMAN; INTRAOCULAR HEMORRHAGE; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MICTURITION DISORDER; PHARMACOGENETICS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER;

EYE DISEASES; GENETIC VARIATION; GENOTYPE; GLAUCOMA; HUMANS; INDIVIDUALIZED MEDICINE; MACULAR DEGENERATION; OPHTHALMIC SOLUTIONS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 77955550909     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-010-1333-x     Document Type: Review

References (54)

1. J Lazarou BH Pomeranz PN Corey 1998 Incidence of adverse drug reactions in hospitalized patients: a meta analysis of prospective studies JAMA 279 1200 1205 10.1001/jama.279.15.1200 1:STN:280:DyaK1c3hsFSnsQ%3D%3D 9555760 (Pubitemid 28193431)
2. H Dormann A Neubert M Criegee-Rieck T Egger M Radespiel-Troger T Azaz-Livshits M Levy K Brune EG Hahan 2004 Readmissions and adverse drug reactions in internal medicine: the economic impact J Int Med 255 653 663 10.1111/j.1365-2796.2004.01326.x 1:STN:280:DC%2BD2c3ltVSltQ%3D%3D (Pubitemid 38703584)
3. BS Shastry 2007 SNPs in disease gene mapping, medicinal drug development and evolution J Hum Genet 52 871 880 10.1007/s10038-007-0200-z 1:CAS:528:DC%2BD2sXht1ejsb%2FI 17928948 (Pubitemid 350112490)
4. BS Shastry 2006 Pharmacogenetics and the concept of individualized medicine Pharmacogenomics J 6 16 21 10.1038/sj.tpj.6500338 1:CAS:528: DC%2BD28XjtVyltw%3D%3D 16302022 (Pubitemid 43118306)
5. BS Shastry 2005 Genetic diversity and new therapeutic concepts J Hum Genet 50 321 328 10.1007/s10038-005-0264-6 1:CAS:528:DC%2BD2MXovVOitLY%3D 16041496 (Pubitemid 41206923)
6. BS Shastry 2004 Role of SNP/haplotype map in gene discovery and drug development: an overview Drug Dev Res 62 142 150 10.1002/ddr.10377 (Pubitemid 39578608)
7. BS Shastry 2003 SNPs and haplotypes: genetic markers for disease and drug response Int J Mol Med 11 379 382 1:CAS:528:DC%2BD3sXhslKqtLs%3D 12579344
8. HL McLeod WE Evans 2001 Pharmacogenomics: unlocking the human genome for better drug therapy Ann Rev Pharmacol Toxicol 41 101 121 10.1146/annurev. pharmtox.41.1.101 1:CAS:528:DC%2BD3MXjsVaqsbg%3D (Pubitemid 32385884)
9. A Iida S Saito A Sekine C Mishima Y Kitamura K Kondo S Harigae S Osawa Y Nakamura 2003 Catalog of 668 SNPs detected among 31 genes encoding potential drug targets on the cell surface J Hum Genet 48 23 46 10.1007/s100380300004 1:CAS:528:DC%2BD3sXovFahsw%3D%3D 12560875 (Pubitemid 36205643)
10. SE Moroi H Jr 2008 Progress toward personalized medicine for age-related macular degeneration Ophthalmology 115 925 926 10.1016/j.ophtha.2008.04.020 18519068 (Pubitemid 351749711)
11. JL Wiggs 2008 Genomic promise: personalized medicine for ophthalmology Arch Ophthalmol 126 422 423 10.1001/archopht.126.3.422 18332327 (Pubitemid 351398472)
12. CA McCarty 2004 The promise and challenges of personalized medicine for eye diseases Clin Exp Ophthalmol 32 236 237 10.1111/j.1442-9071.2004.00833.x (Pubitemid 38930980)
13. SG Schwartz WF Mieler 2002 Medications and retinal toxicity Ophthalmol Clin North Am 15 517 528 10.1016/S0896-1549(02)00051-2 12515084 (Pubitemid 36076607)
14. PN Baird GS Hageman RHG Franzco 2009 New era for personalized medicine: the diagnosis and management of age-related macular degeneration Clin Exp Ophthalmol 37 814 821 10.1111/j.1442-9071.2009.02136.x
15. RJ Klein C Zeiss EY Chew JY Tsai RS Sackler C Haynes AK Henning JP SanGiovanni SM Mane ST Mayne MB Bracken FL Ferris J Ott C Barnstable J Hoh 2005 Complement factor H polymorphism in age-related macular degeneration Science 308 385 389 10.1126/science.1109557 1:CAS:528:DC%2BD2MXjtFOntLs%3D 15761122 (Pubitemid 40530070)
16. AO Edwards RIII Ritter KJ Abel A Manning C Panhuysen LA Farrer 2005 Complement factor H polymorphism and age-related macular degeneration Science 308 421 424 10.1126/science.1110189 1:CAS:528:DC%2BD2MXjtFOntLw%3D 15761121 (Pubitemid 40530082)
17. JL Haines MA Hauser S Schmidt WK Scott LM Olson P Gallins KL Spencer SY Kwan M Noureddine JR Gilbert N Schnetz-Boutaud A Agarwal EA Postel MA Pericak-Vance 2005 Complement factor H variant increases the risk of age-related macular degeneration Science 308 419 421 10.1126/science.1110359 1:CAS:528:DC%2BD2MXjtFOntL8%3D 15761120 (Pubitemid 40530081)
18. S Zareparsi KE Branham M LI S Shah RJ Klein J Ott J Hoh GR Abecasis A Swaroop 2005 Strong association of the Y402H variant in complement factor H at 1q32 with susceptibility to age-related macular degeneration Am J Hum Genet 77 149 153 10.1086/431426 1:CAS:528:DC%2BD2MXlsFCmuro%3D 15895326 (Pubitemid 40848046)
19. A Rivera SA Fisher LG Fritsche CN Keilhauer P Lichtner T Meitinger BH Weber 2005 Hypothetical LOC 387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk Hum Mol Genet 14 3227 3236 10.1093/hmg/ddi353 1:CAS:528:DC%2BD2MXhtFCjtL%2FE 16174643 (Pubitemid 41631297)
20. A Dewan M Liu S Hartman SS Zhang DT Liu C Zhao PO Tam WM Chan DS Lam M Snyder C Barnstable CP Pang J Hoh 2006 HTRA1 promoter polymorphism in wet age-related macular degeneration Science 314 982 992 10.1126/science.1133807 (Pubitemid 44749943)
21. BS Shastry 2006 Further support for the common variants in complement factor H (Y402H) and LOC 387715 (A69S) gene as major risk factors for the exudative age-related macular degeneration Ophthalmologica 220 291 295 10.1159/000094617 16954704 (Pubitemid 44352647)
22. BS Shastry 2007 Assessment of the contribution of LOC 387715 gene polymorphism in a family with exudative age-related macular degeneration and heterozygous CFH variant (Y402H) J Hum Genet 52 384 387 10.1007/s10038-007-0120- y 17285240 (Pubitemid 46496294)
23. N Patel T Adewovin NV Chong 2008 Age-related macular degeneration: a perspective on genetic studies Eye 22 768 776 10.1038/sj.eye.6702844 1:STN:280:DC%2BD1cznslOqtg%3D%3D 17491602 (Pubitemid 351850512)
24. DM Brown M Michels PK Kaiser JS Heier JP Sy T Ianchulev 2009 Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two year results of the ANCHOR study Ophthalmology 116 57 65 10.1016/j.ophtha.2008.10.018 19118696
25. DM Brown PK Kaiser M Michels G Soubrane JS Heier RY Kim JP Sy S Schneider ANCHOR study group 2006 Ranibizumab verses verteporfin for neovascular age-related macular degeneration N Engl J Med 355 1432 1444 10.1056/NEJMoa062655 1:CAS:528:DC%2BD28XhtVGgtrrI 17021319 (Pubitemid 44511558)
26. PJ Rosenfeld DM Brown JS Heier DS Boyer PK Kaiser CY Chung RY Kim MARINA study group 2006 Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 1419 1431 10.1056/NEJMoa054481 1:CAS:528:DC%2BD28XhtVGgtr3M 17021318 (Pubitemid 44511557)
27. R Steinbrook 2006 The price of sight-ranibizumab, bevacizumab and the treatment of macular degeneration N Engl J Med 355 1409 1412 10.1056/NEJMp068185 1:CAS:528:DC%2BD28XhtVGgsb3L 17021315 (Pubitemid 44511554)
28. A Sheybani S Kymes S Schlief R Apte 2009 Vascular events in patients with age-related macular degeneration treated with intraocular bevacizumab Retina 29 1404 1408 10.1097/IAE.0b013e3181b32d13 19898178
29. MA Brantley Jr AM Fang JM King A Tewari SM Kymes A Shiels 2007 Association of complement factor H and LOC 387715 genotype with response of exudative age-related macular degeneration to intravitreal bevacizumab Ophthalmology 114 2168 2173 10.1016/j.ophtha.2007.09.008 18054635 (Pubitemid 350181136)
30. AY Lee AK Rava SM Kvmes A Shiels MA Brantley Jr 2009 Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab Br J Ophthalmol 93 610 613 10.1136/bjo.2008.150995 1:STN:280:DC%2BD1M3pvFahsA%3D%3D 19091853
31. SS Lynch CM Cheng 2007 Bevacizumab for neovascular ocular diseases Ann Pharmacother 41 614 625 10.1345/aph.1H316 1:CAS:528:DC%2BD2sXltlOnsrs%3D 17355998 (Pubitemid 46625484)
32. F Parmeggiani C Costagliola D Gemmati S D'Angelo P Perri GL Scapoli L Catozzi F Federici A Sebastiani C Incorvaia 2007 Productive role of coagulation-balance gene polymorphisms in the efficacy of photodynamic therapy with verteporfin for classic choroidal neovascularization secondary to age-related macular degeneration Pharmacogenet Genomics 17 1039 1046 10.1097/FPC.0b013e3282f12a4e 1:CAS:528:DC%2BD2sXhsVWiu7%2FI 18004208 (Pubitemid 351339488)
33. F Parmeggiani D Gemmati C Costagliola A Sebastiani C Incorvaia 2009 Predictive role of C677T MTHFR polymorphism in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration Pharmacogenomics 10 81 95 10.2217/14622416.10.1.81 1:CAS:528:DC%2BD1cXhsFCisLnI 19102718
34. RK Koenekoop I Lopez AT den Hollander R Allikmets FP Cremers 2007 Genetic testing for retinal dystrophies and dysfunctions: benefits, dilemmas and solutions Clin Exp Ophthalmol 35 473 485 10.1111/j.1442-9071.2007.01534.x (Pubitemid 47162765)
35. M Maeda Y Fujio J Azuma 2006 MTHFR gene polymorphism and diabetic retinopathy Curr Diabetes Rev 2 467 476 1:CAS:528:DC%2BD28Xht1Wjtr7J 18220649
36. SP Seitsonen IE Jarvela S Meri PV Tommila PH Ranta IJ Immonen 2007 The effect of complement factor H Y402H polymorphism on the outcome of photodynamic therapy in age-related macular degeneration Eur J Ophthalmol 17 943 949 1:STN:280:DC%2BD2sjhtFGitA%3D%3D 18050121
37. X Feng J Xiao B Longville AX Tan XN Wu MN Cooper IL McAllister T Isaacs LJ Palmer IJ Constable 2009 Complement factor H Y402H and C-reactive protein polymorphism and photodynamic therapy response in age-related macular degeneration Ophthalmology 116 1908 1912 10.1016/j.ophtha.2009.03.011 19692124
38. M Laine JH Seitsonen K Haapasalo MJ Lehtinen N Lindeman DH Anderson PT Johnson I Jarvela TS Jokiranta GS Hageman I Immonen S Meri 2007 Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein J Immunol 178 3831 3836 1:CAS:528:DC%2BD2sXisVGjtrc%3D 17339482
39. I Immonen S Seitsonen P Tommila T Kangas-Kontio S Kakko ER Savolainen MJ Savolainen MJ Liinamaa 2010 Vascular endothelial growth factor gene variation and the response to photodynamic therapy in age-related macular degeneration Ophthalmology 117 103 108 10.1016/j.ophtha.2009.06.037 19896188
40. ML Klein PJ Francis B Rosner R Reynolds SC Hamon DW Schultz J Ott JM Seddon 2008 CFH and LOC 387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration Ophthalmology 115 1019 1025 10.1016/j.ophtha.2008.01.036 18423869
41. RN Weinberg PT Khaw 2004 Primary open-angle glaucoma Lancet 363 1711 1720 10.1016/S0140-6736(04)16257-0 (Pubitemid 38670330)
42. WM Grant 1963 Glaucoma from topical corticosteroids Arch Ophthalmol 70 445 446 1:STN:280:DyaF2c%2Fjs1GjsQ%3D%3D 14078862
43. B Becker KA Hahn 1964 Topical corticoids and heredity in primary open-angle glaucoma Am J Ophthalmol 57 543 551 1:STN:280:DyaF2c%2Fpslajuw%3D%3D 14139296
44. V Szabo G Borgulya T Filkorn J Majnik I Banyasz ZZ Nagy 2007 The variant N363S of glucocorticoid receptor in steroid-induced ocular hypertension in Hungarian patients treated with photorefractive keratectomy Mol Vis 13 659 666 1:CAS:528:DC%2BD2sXms1Kksbw%3D 17563720
45. SM Gerzenstein MT Pletcher AC Cervino NF Tsinoremas B Young CA Puliafito ME Fini SG Schwartz 2008 Glucocorticoid receptor polymorphisms and intraocular pressure response to intravitreal triamcinolone acetonide Ophthalmic Genet 29 166 170 10.1080/13816810802320217 1:CAS:528:DC%2BD1MXltFCltA%3D%3D 19005987
46. Y Yang K Wu H Yuan M Yu 2009 Cytochrome oxidase 2D6 gene polymorphism in primary open-angle glaucoma with various effects to ophthalmic timolol J Ocul Pharmacol Ther 25 163 171 10.1089/jop.2008.0028 1:CAS:528:DC%2BD1MXkt1Cjurk%3D 19284319
47. T Nieminen H Uusitalo J Maenpaa V Turjanmaa A Rane S Lundgren A Ropo R Rontu T Lehtimaki M Kahonen 2005 Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol Eur J Clin Pharmacol 61 811 819 10.1007/s00228-005-0052-4 1:CAS:528:DC%2BD2MXht1Gqu7zI 16315032 (Pubitemid 41720269)
48. CA McCarty JK Burmester BN Mukesh RB Patchett RA Wilke 2008 Intraocular pressure response to topical beta blockers associated with an ADRB2 single-nucleotide polymorphism Arch Ophthalmol 126 959 963 10.1001/archopht.126. 7.959 1:CAS:528:DC%2BD1cXptFymu7s%3D 18625943 (Pubitemid 352008379)
49. G Fuchsjager-Mayrl O Markovic D Losert T Lucus V Wachek M Muller L Schmutterer 2005 Polymorphism of the beta-2 adrenoceptor and IOP lowering potency of topical timolol in healthy subjects Mol Vis 11 811 815 1:CAS:528:DC%2BD28XitFemtLg%3D 16205624
50. M Sakurai T Higashide M Takahashi K Sugiyama 2007 Association between genetic polymorphisms of the prostaglandin F2alpha receptor gene and response to latanoprost Ophthalmology 114 1039 1045 10.1016/j.ophtha.2007.03.025 17467803 (Pubitemid 46829392)
51. IM MacDonald 2009 Pharmacogenetics-getting closer Open Ophthalmol J 3 46 54 10.2174/1874364100903020046 1:CAS:528:DC%2BD1MXhtl2htL3K 19816587
52. NC McLaren SE Moroi 2003 Clinical implications of pharmacogenetics for glaucoma therapeutics Pharmacogenomics J 3 197 201 10.1038/sj.tpj.6500181 1:CAS:528:DC%2BD3sXmsFWisrk%3D 12931133 (Pubitemid 37160976)
53. FW Frueh D Gurwitz 2004 From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community Pharmacogenomics 5 571 579 10.1517/14622416.5.5.571 15212593 (Pubitemid 39023073)
54. TD Richmond 2008 The current status and future potential of personalized diagnostics: streamlining a customized process Biotechnol Ann Rev 14 411 422 10.1016/S1387-2656(08)00015-X (Pubitemid 351903460)